Authors
Latest:
Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.
Latest:
Lower EDIC May Improve Local Tumor Control in Lung CancerDecreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
Latest:
Oncology Peer Review On-The-Go: Cancer Pain and Opioid Use DisorderAuthors Daniel C. McFarland, DO, and Kirk Harris, MD, spoke with CancerNetwork® about their manuscript on cancer pain’s relationship with opioid use disorder that was recently published in the journal ONCOLOGY®.
Latest:
Addressing Resistance to Targeted Therapies in Metastatic Colorectal CancerInvestigators discuss the use of targeted therapies to treat metastatic colorectal cancer.
Latest:
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma TreatmentZenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Latest:
Bemarituzumab Regimen Prolongs Survival in Advanced Gastric/GEJ CancerThe overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.
Latest:
A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity ReactionStacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.
Latest:
Value of Geriatric Assessment in Patients With Genitourinary CarcinomaThis work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.
Latest:
Future Perspectives on MRD Testing in Colorectal CancerThe expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.
Latest:
A Multidisciplinary Approach to Treating Resectable NSCLCSurgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.
Latest:
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon CancerThis case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Latest:
Identifying and Pursuing Optimization of ADC Treatment in CancerAntibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Latest:
Current Treatment of Peripheral T-cell LymphomaThis review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
Latest:
Kelley Lauren Coffman, MD, on Key Takeaways from a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETsThe hospitalist at Memorial Sloan Kettering Cancer Center discussed what she believes is most important for practicing oncologists to understand about a study of 177Lu-DOTATATE in well-differentiated, high-grade neuroendocrine tumors.
Latest:
Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary InfectionThis case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.
Latest:
Objective Data Highlight Substantial Benefits With Mirdametinib in NF1-PNFindings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
